Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study
Clinical Microbiology and Infection · 2023
DOI: 10.1016/j.cmi.2023.01.005 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Clinical Microbiology and Infection, 2023. Verfasst von Nasreen Hassoun-Kheir und 12 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases and Infection Control Unit, Rambam Health Care Campus, Haifa, Israel; Geneva University Hospitals and Faculty of Medicine Geneva,…. Hauptthemen laut MEDLINE: Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae, Gammaproteobacteria. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: We aimed to assess the association between carbapenem-resistant Enterobacterales (CRE) colonization pressure and carbapenem exposure and acquisition of carbapenemase-producing Enterobacterales (CPE) and non-carbapenemase-producing carbapenem-resistant Enterobacterales (non-CP-CRE). METHODS: We conducted a parallel 1:2 matched case-control study at Rambam Health Care Campus, Israel, from January 2014 to June 2017. The cases included all adults who acquired CPE or non-CP-CRE in hospital. The controls were hospitalized patients who were negative for CRE on screening and matched by age, hospitalization division and the number of hospitalization days 90 days prior to CRE screening. The exposures of interest were high CRE colonization pressure, defined as a higher-than-median proportion of CRE carriers in the concurrent patient's department before acquisition, and carbapenem exposure, assessed as days of treatment. Conditional logistic regression was used for analyses of CPE and non-CP-CRE. RESULTS: In total, 1058 patients were included: 278 CPE and 75 non-CP-CRE cases, matched to 556 and 149 controls, respectively. High CRE colonization pressure was associated with CPE acquisition (adjusted odds ratio [aOR], 2.6; 95% CI, 1.69-4.02); however, the duration of carbapenem treatment was not (aOR, 1.004; 95% CI, 0.98-1.03; 1-day increment). The duration of carbapenem treatment was significantly associated with non-CP-CRE acquisition (aOR per day, 1.07; 95% CI, 1.03-1.11). A source patient was identified significantly more frequently in epidemiological acquisition investigations of CPE than in those of non-CP-CRE (107/240, 44.6% vs. 18/64, 28.1%, respectively; p 0.017). CONCLUSIONS: CPE acquisition was associated with horizontal transmission, whereas non-CP-CRE was associated with carbapenem exposure. Differences in the drivers of acquisition mandate tailored infection prevention efforts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases and Infection Control Unit, Rambam Health Care Campus, Haifa, Israel; Geneva University Hospitals and Faculty of Medicine Geneva, Switzerland. Electronic address: nasreen20@gmail.com.
- Infectious Diseases and Infection Control Unit, Rambam Health Care Campus, Haifa, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
- Sackler Faculty of Medicine, School of Public Health, University of Tel-Aviv, Tel-Aviv, Israel.
- Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
- Geneva University Hospitals and Faculty of Medicine Geneva, Switzerland.
- Infectious Diseases and Infection Control Unit, Rambam Health Care Campus, Haifa, Israel.
Zitieren
APA
Hassoun-Kheir, N., Hussein, K., Karram, M., Saffuri, M., Badaan, S., Peleg, S., de Kraker, M. E. A., Aboelhega, W., Warman, S., Alon, T., Eluk, O., Geffen, Y., & Paul, M. (2023). Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2023.01.005
Vancouver
Hassoun-Kheir N, Hussein K, Karram M, Saffuri M, Badaan S, Peleg S, et al. Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study. Clinical Microbiology and Infection. 2023. doi:10.1016/j.cmi.2023.01.005
BibTeX
@article{HassounKheir2023,
author = {Hassoun-Kheir, Nasreen and Hussein, Khetam and Karram, Marianne and Saffuri, Maram and Badaan, Sally and Peleg, Shani and de Kraker, Marlieke E A and Aboelhega, Worood and Warman, Sigal and Alon, Tamar and Eluk, Orna and Geffen, Yuval and Paul, Mical},
title = {Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study},
journal = {Clinical Microbiology and Infection},
year = {2023},
doi = {10.1016/j.cmi.2023.01.005}
}
EUVIMED